264 related articles for article (PubMed ID: 30045981)
1. Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus.
Nyström K; Wanrooij PH; Waldenström J; Adamek L; Brunet S; Said J; Nilsson S; Wind-Rotolo M; Hellstrand K; Norder H; Tang KW; Lagging M
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045981
[TBL] [Abstract][Full Text] [Related]
2. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.
Rembeck K; Waldenström J; Hellstrand K; Nilsson S; Nyström K; Martner A; Lindh M; Norkrans G; Westin J; Pedersen C; Färkkilä M; Langeland N; Buhl MR; Mørch K; Christensen PB; Lagging M
Hepatology; 2014 Jun; 59(6):2131-9. PubMed ID: 24519039
[TBL] [Abstract][Full Text] [Related]
3. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
Thompson AJ; Santoro R; Piazzolla V; Clark PJ; Naggie S; Tillmann HL; Patel K; Muir AJ; Shianna KV; Mottola L; Petruzzellis D; Romano M; Sogari F; Facciorusso D; Goldstein DB; McHutchison JG; Mangia A
Hepatology; 2011 Feb; 53(2):389-95. PubMed ID: 21274861
[TBL] [Abstract][Full Text] [Related]
4. Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype.
Peltenburg NC; Bakker JA; Vroemen WH; de Knegt RJ; Leers MP; Bierau J; Verbon A
Clin Chem Lab Med; 2015 Nov; 53(12):2021-9. PubMed ID: 25968438
[TBL] [Abstract][Full Text] [Related]
5. Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines.
Jimmerson LC; Clayton CW; MaWhinney S; Meissner EG; Sims Z; Kottilil S; Kiser JJ
Antiviral Res; 2017 Feb; 138():79-85. PubMed ID: 27956135
[TBL] [Abstract][Full Text] [Related]
6. Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis.
Ortega-Prieto AM; Sheldon J; Grande-Pérez A; Tejero H; Gregori J; Quer J; Esteban JI; Domingo E; Perales C
PLoS One; 2013; 8(8):e71039. PubMed ID: 23976977
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of Erythrocyte Ribavirin Triphosphate Concentrations Depends on the ITPA Genotype.
Tanaka Y; Inoue A; Mizunuma T; Matsumura H; Yokomori H; Komiyama T; Otori K
Ther Drug Monit; 2019 Aug; 41(4):497-502. PubMed ID: 30817703
[TBL] [Abstract][Full Text] [Related]
8. Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.
Amjed S; Saleem HGM; Ullah S; Latif S; Shabana ; Jafar J; Waqar AB
BMC Infect Dis; 2024 Mar; 24(1):301. PubMed ID: 38468199
[TBL] [Abstract][Full Text] [Related]
9. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.
Pineda-Tenor D; García-Álvarez M; Jiménez-Sousa MA; Vázquez-Morón S; Resino S
J Transl Med; 2015 Oct; 13():320. PubMed ID: 26438033
[TBL] [Abstract][Full Text] [Related]
10. Reduced ITPase activity and favorable IL28B genetic variant protect against ribavirin-induced anemia in interferon-free regimens.
Vasanthakumar A; Davis JW; Abunimeh M; Söderholm J; Zha J; Dumas EO; Cohen DE; Waring JF; Lagging M
PLoS One; 2018; 13(5):e0198296. PubMed ID: 29851985
[TBL] [Abstract][Full Text] [Related]
11. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.
Thompson AJ; Fellay J; Patel K; Tillmann HL; Naggie S; Ge D; Urban TJ; Shianna KV; Muir AJ; Fried MW; Afdhal NH; Goldstein DB; McHutchison JG
Gastroenterology; 2010 Oct; 139(4):1181-9. PubMed ID: 20547162
[TBL] [Abstract][Full Text] [Related]
12. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function.
Hitomi Y; Cirulli ET; Fellay J; McHutchison JG; Thompson AJ; Gumbs CE; Shianna KV; Urban TJ; Goldstein DB
Gastroenterology; 2011 Apr; 140(4):1314-21. PubMed ID: 21199653
[TBL] [Abstract][Full Text] [Related]
13. Analysis of human ITPase nucleobase specificity by site-directed mutagenesis.
Gall AD; Gall A; Moore AC; Aune MK; Heid S; Mori A; Burgis NE
Biochimie; 2013 Sep; 95(9):1711-21. PubMed ID: 23770441
[TBL] [Abstract][Full Text] [Related]
14. ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection.
Maan R; van der Meer AJ; Brouwer WP; Plompen EP; Sonneveld MJ; Roomer R; van der Eijk AA; Groothuismink ZM; Hansen BE; Veldt BJ; Janssen HL; Boonstra A; de Knegt RJ
PLoS One; 2015; 10(10):e0139317. PubMed ID: 26441325
[TBL] [Abstract][Full Text] [Related]
15. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.
Naggie S; Rallon NI; Benito JM; Morello J; Rodriguez-Novoa S; Clark PJ; Thompson AJ; Shianna KV; Vispo E; McHutchison JG; Goldstein DB; Soriano V
J Infect Dis; 2012 Feb; 205(3):376-83. PubMed ID: 22158703
[TBL] [Abstract][Full Text] [Related]
16. Absence of interferon-λ 4 enhances spontaneous clearance of acute hepatitis C virus genotypes 1-3 infection.
Waldenström J; Kåberg M; Alanko Blomé M; Widell A; Björkman P; Nilsson S; Hammarberg A; Weiland O; Nyström K; Lagging M
Scand J Gastroenterol; 2021 Jul; 56(7):855-861. PubMed ID: 34034600
[TBL] [Abstract][Full Text] [Related]
17. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.
Holmes JA; Roberts SK; Ali RJ; Dore GJ; Sievert W; McCaughan GW; Crawford DH; Cheng WS; Weltman MD; Bonanzinga S; Visvanathan K; Sundararajan V; Desmond PV; Bowden DS; Matthews GV; Thompson AJ;
Hepatology; 2014 Jun; 59(6):2152-60. PubMed ID: 24449403
[TBL] [Abstract][Full Text] [Related]
18. Inosine triphosphate pyrophosphatase: A guardian of the cellular nucleotide pool and potential mediator of RNA function.
Schroader JH; Handley MT; Reddy K
Wiley Interdiscip Rev RNA; 2023; 14(5):e1790. PubMed ID: 37092460
[TBL] [Abstract][Full Text] [Related]
19. Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study.
Liu Z; Wang Y; Li H; Wang X; Wang X; Xu X; Ma C; Wang J
Medicine (Baltimore); 2023 Oct; 102(43):e35508. PubMed ID: 37904484
[TBL] [Abstract][Full Text] [Related]
20. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.
Azakami T; Hayes CN; Sezaki H; Kobayashi M; Akuta N; Suzuki F; Kumada H; Abe H; Miki D; Tsuge M; Imamura M; Kawakami Y; Takahashi S; Ochi H; Nakamura Y; Kamatani N; Chayama K
J Med Virol; 2011 Jun; 83(6):1048-57. PubMed ID: 21503919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
